


## PHARMACEUTICAL 2018

## Immune Therapeutics Inc. Rank 318 of 349





## PHARMACEUTICAL 2018

## Immune Therapeutics Inc. Rank 318 of 349

The relative strengths and weaknesses of Immune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2,206% points. The greatest weakness of Immune Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 358% points.

The company's Economic Capital Ratio, given in the ranking table, is -773%, being 495% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	193
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,299
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	2,683
Other Liabilities	0
Other Net Income	-2,020
Property and Equipment	2.5
Research and Development	399
Revenues	0
Selling, General and Administrative Expense	2,832

Output Variable	Value in 1000 USD
Assets	196
Liabilities	11,299
Expenses	5,914
Stockholders Equity	-11,103
Net Income	-7,934
Comprehensive Net Income	-7,934
Economic Capital Ratio	-773%